desipramine has been researched along with Anemia, Hemolytic, Acquired in 1 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tissot, R | 1 |
| Gaillard, JM | 1 |
| Guggisberg, M | 1 |
| Gauthier, G | 1 |
| de Ajuriaguerra, J | 1 |
1 other study available for desipramine and Anemia, Hemolytic, Acquired
| Article | Year |
|---|---|
[Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
Topics: Adult; Aged; Anemia, Hemolytic; Aromatic Amino Acid Decarboxylase Inhibitors; Blood Cell Count; Carb | 1969 |